Key Takeaways
- FDA has granted approval for Corcept’s Lifyorli (relacorilant) to treat platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
- Shares of CORT climbed approximately 40% following Wednesday’s announcement
- Regulatory review concluded 2.5 months earlier than the scheduled target date
- Trial results demonstrated median overall survival of 16 months compared to 11.9 months with monotherapy
- The company currently holds a market capitalization near $3.97 billion with consensus analyst targets at $66.80
Corcept Therapeutics received regulatory clearance from the FDA on Wednesday for its oncology drug relacorilant, marketed as Lifyorli. The treatment has been authorized for use alongside nab-paclitaxel in adult patients diagnosed with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Corcept Therapeutics Incorporated, CORT
Shares experienced a dramatic rally of approximately 40% following the announcement — marking one of the most significant single-session gains in the biotechnology sector this year.
The authorized indication targets patients who have completed one to three previous systemic therapy regimens, with at least one course including bevacizumab. While this represents a narrowly defined patient group, it addresses a critical unmet need in a challenging-to-treat cancer category.
The regulatory agency completed its evaluation 2.5 months before the designated action date. Such expedited approvals are uncommon and typically indicate the FDA identified compelling evidence of clinical benefit.
Clinical Trial Results
The regulatory decision was supported by findings from the ROSELLA trial — a multi-site investigation involving 381 participants. The study randomized patients evenly between relacorilant combined with nab-paclitaxel versus nab-paclitaxel monotherapy.
Patients receiving the combination regimen achieved a median progression-free survival of 6.5 months compared to 5.5 months in the control arm. Median overall survival reached 16 months with the dual therapy versus 11.9 months for patients receiving nab-paclitaxel alone.
While these improvements may appear incremental, they represent meaningful progress in a clinical context where therapeutic alternatives remain scarce. Platinum-resistant ovarian cancer presents substantial treatment challenges, making any survival benefit clinically significant.
Relacorilant functions as a glucocorticoid receptor antagonist. The recommended regimen consists of 150 mg administered orally once daily for three consecutive days surrounding each nab-paclitaxel infusion.
Nab-paclitaxel is administered at 80 mg/m² intravenously on days 1, 8, and 15 within a 28-day treatment cycle.
Safety Profile and Adverse Events
The product labeling specifies contraindications for individuals requiring corticosteroids for critical life-sustaining indications. Frequently reported adverse reactions encompass decreased hemoglobin and neutrophil counts, fatigue, nausea, diarrhea, thrombocytopenia, skin rash, and reduced appetite.
From a financial perspective, the company presents a varied profile. Revenue has expanded 22.3% over the trailing three-year period. Net profit margin registers at 13.09% while gross margin stands at an impressive 98.3%.
Earnings growth, however, contracted 33.3% year-over-year. The price-to-earnings multiple currently sits at 45.49, positioning it toward the elevated end of the valuation spectrum.
The company’s balance sheet appears robust — featuring a current ratio of 2.92 and minimal leverage with a debt-to-equity ratio of just 0.01.
Institutional investors control 72.18% of outstanding shares. Wall Street’s consensus price target of $66.80 implies additional upside potential remains despite Wednesday’s sharp advance.
Corcept’s Altman Z-Score registers at 14.14, indicating strong financial health. The Beneish M-Score of -2.81 suggests low probability of accounting manipulation.
Prior to Wednesday’s session, the 50-day moving average stood at $37.32, while the RSI reading of 41.26 showed the stock was not in overbought territory before the surge.
